Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1675]

ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer

ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer

ASCO 2022: Ibrutinib improves progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma

ASCO 2022: Ibrutinib improves progression-free survival by 50% for older patients with newly diagnosed mantle cell...

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast cancer

ASCO 2022: Study offers guidance for future trials of adjuvant therapy for patients with early HR+/HER2- breast...

Molecular profiling identifies new high-risk subtype of paediatric liver cancer

Molecular profiling identifies new high-risk subtype of paediatric liver cancer

ASCO 2022: Desmoplastic melanoma responds to PD-1 blockade immunotherapy

ASCO 2022: Desmoplastic melanoma responds to PD-1 blockade immunotherapy

ASCO 2022: Cell-free DNA methylation used to predict chemo benefit in bladder cancer

ASCO 2022: Cell-free DNA methylation used to predict chemo benefit in bladder cancer

DWI for detection of locally recurrent pancreatic cancer

DWI for detection of locally recurrent pancreatic cancer

Cancer patients face greater risks from abdominal aneurysm repair

Cancer patients face greater risks from abdominal aneurysm repair

Artificial intelligence helps physicians better assess the effectiveness of bladder cancer treatment

Artificial intelligence helps physicians better assess the effectiveness of bladder cancer treatment

Less prostate cancer screening reduces overdiagnosis but may miss aggressive cases

Less prostate cancer screening reduces overdiagnosis but may miss aggressive cases

More from ecancer